drugset / Trial / NCT01421134

Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose

NCT01421134 ↗

Phase 3 Completed 211 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.

Timeline

Start
2011-09
Primary completion
2014-10
Completion
2014-10

Outcome

Met primary endpoint

paper Lurasidone significantly reduced mean MADRS total scores at week 6 endpoint (-20.5 vs -13.0; P < .001). PMID 30086213 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 20 mg —
Subject Lurasidone Small molecule 40 mg —
Subject Lurasidone Small molecule 60 mg —